• Olaratumab fails to show benefit in platinum-resistant ovarian cancer
    Olaratumab fails to show benefit in platinum-resistant ovarian cancer

    Randomised study of olaratumab plus liposomal doxorubicin in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.

  • Recurrent ovarian cancer: cabozantinib fails phase 2 trial

    OS and toxicities were worse vs weekly paclitaxel.

  • Expert Commentary – Ovarian cancer: main improvements in 2018

    PARP inhibitors in recurrent ovarian cancer increase PFS. But if used more and more as first-line therapy, what will we do with PARP inhibitors in later lines?

  • BRCA+ ovarian cancer: heavily treated patients retain chemosensitivity in Spanish study

    Primary PFI, platinum-based CT, and PARP-inhibitors strongly predict outcomes.

  • KEYNOTE-028: pembrolizumab shows efficacy in ovarian cancer

    Active in advanced recurrent disease, with safety profile consistent vs other studies.

  • EOC: 1 in 7 women develop VTE within 6 months of debulking surgery

    Guidelines do not recommend VTE prophylaxis for outpatients.

  • Advanced EOC: timely ACT completion yields optimal outcomes

    Shorter regimens and delays of >4 weeks attenuate survival benefit.

  • Ovarian cancer: add-on BVZ boosts PFS regardless of residual disease

    Post hoc analysis of ICON7 shows OS improvement in high-risk group.

  • Simple ovarian cysts not tied to cancer

    Can be considered normal findings, no surveillance needed.

  • Tubo-ovarian cancer: NACT, primary debulking offer similar OS

    NACT superior for stage IV disease in pooled analysis of EORTC 55971, CHORUS.

  • BRCA+ ovarian cancer: maintenance olaparib boosts PFS in SOLO1

    PFS improved by 70% in advanced disease.

  • ESMO 2018 – PARP-inhibition in women with newly diagnosed advanced BRCA-mutated ovarian cancer increases PFS at three years to 60%

    Maintenance therapy with olaparib decreased the risk of disease progression or death by 70% in the SOLO1 trial

  • ESMO 2018 – The value of adding bevacizumab to carboplatin/pegylated liposomal doxorubicin when treating recurrent ovarian cancer

    A new combination regimen based on the three drugs has been shown to provide a significant benefit in progression-free survival compared to standard combination regimens

  • Ovarian cancer: BRCA+ patients derive greater benefit from IP chemotherapy

    Data show "dramatic improvement" in PFS and OS vs BRCA-negative patients.

  • Load more